Abstract
Stroke is the third leading cause of death and the leading cause of disability in contemporary society. Aneurysmal subarachnoid hemorrhage (aSAH) is a hemorrhagic stroke which accounts for 7% of all stroke cases and 22 to 25% of cerebrovascular deaths. Aneurysmal subarachnoid hemorrhage is a very complex disease and many controversies on its pathophysiology and management have not yet been settled. The aim of this review is to present the most recent evidence-based advances in the pathophysiology and perioperative management of aSAH.
Keywords: Subarachnoid hemorrhage, vasospasm, stroke, delayed neurologic deficits.
Current Pharmaceutical Design
Title:Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Volume: 19 Issue: 32
Author(s): Ehab Farag, Zeyd Ebrahim, David Traul, Irene Katzan and Edward Manno
Affiliation:
Keywords: Subarachnoid hemorrhage, vasospasm, stroke, delayed neurologic deficits.
Abstract: Stroke is the third leading cause of death and the leading cause of disability in contemporary society. Aneurysmal subarachnoid hemorrhage (aSAH) is a hemorrhagic stroke which accounts for 7% of all stroke cases and 22 to 25% of cerebrovascular deaths. Aneurysmal subarachnoid hemorrhage is a very complex disease and many controversies on its pathophysiology and management have not yet been settled. The aim of this review is to present the most recent evidence-based advances in the pathophysiology and perioperative management of aSAH.
Export Options
About this article
Cite this article as:
Farag Ehab, Ebrahim Zeyd, Traul David, Katzan Irene and Manno Edward, Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113199990062
DOI https://dx.doi.org/10.2174/13816128113199990062 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal
Current Drug Targets Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design Vascular microRNAs
Current Drug Targets Development and Evaluation of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) and Polycaprolactone Microparticles of Nimodipine
Current Pharmaceutical Design Role of Statins in Peri-Operative Medicine
Current Drug Targets Is Flow Diversion the Death of Simple Coiling or Stent-assisted Coiling? A Single-center Experience
Current Neurovascular Research Past and Present Behçet’s Disease Animal Models
Current Drug Targets Prophylactic Neuroprotection
Current Drug Targets Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Landmark-Based Shape Analysis on Middle Cerebral Intracranial Aneurysms: A Geometric Morphometrics Approach to Infer Natural History
Current Neurovascular Research Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Current Vascular Pharmacology Protein-Energy Malnutrition Alters Thermoregulatory Homeostasis and the Response to Brain Ischemia
Current Neurovascular Research The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Glycosaminoglycans as Key Molecules in Atherosclerosis: The Role of Versican and Hyaluronan
Current Medicinal Chemistry Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research